New peanut allergy drug passes first safety check
NCT ID NCT06331728
First seen Nov 14, 2025 · Last updated May 01, 2026 · Updated 14 times
Summary
This study tested a new drug called IGNX001 in 32 adults and older teens with peanut allergy. The main goal was to see if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored for side effects. This is an early-stage trial focused on safety, not yet on whether the drug can prevent allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fiona Stanley Hospital
Murdoch, Western Australia, 6150, Australia
-
Monash Health, Sleep, Allergy, and Immunology
Clayton, Victoria, 3168, Australia
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
St Vincent's Sydney
Darlinghurst, New South Wales, 2010, Australia
Conditions
Explore the condition pages connected to this study.